Loading clinical trials...

PSMA PET for Surveillance After Focal Therapy | Clinical Trials | Clareo Health

RECRUITINGNA

PSMA PET for Surveillance After Focal Therapy

Prospective Evaluation of PSMA PET Imaging in Surveillance Post-Focal Therapy for Prostate Cancer (PSMA-FT Surveillance Study)

NCT07115914•University of Chicago

View on ClinicalTrials.gov

Summary

This study is about adding PSMA PET (Prostate Specific Membrane Antigen- Positron Emission Tomography) to routine magnetic resonance imaging (MRI) scans to help detect prostate cancer recurrence in men who have undergone focal therapy for prostate cancer. PSMA PET and multiparametric (mpMRI are both imaging tests that help detect prostate cancer in the body. A PSMA PET scan, or prostate-specific membrane antigen positron emission tomography scan, is an imaging test that scans and takes pictures of the prostate. PSMA scans use a specialized radioactive imaging dye that sticks to the proteins that are typically found in prostate cancer cells. This imaging dye helps locate areas of prostate cancer anywhere in the body, both inside and outside prostate. An mpMRI, or a multiparametric (mp) MRI scan, is also an imaging test that scans and takes detailed pictures of the prostate. Unlike regular MRIs, an mpMRI produces a more detailed image of the prostate. Similar to PET scans, mpMRI scans also use an imaging dye that helps the pictures of the prostate appear clearer on scans. This study will be funded by Blue Earth Diagnostics, a molecular imaging company based in England.

Detailed Description

People who agree to join the study will be asked to attend study visits for about 12 months after focal therapy. Focal therapy will not be given as part of research in this study. Study participants will receive focal therapy, a follow up MRI and prostate biopsy as part of regular clinical care for their cancer. This research study will add an additional PSMA PET to follow up after focal therapy. Study participants will also be asked to: * Give blood, urine and tissue samples for research purposes. The decision to give tissue samples is optional and not required for participation in study. * Fill out quality of life questionnaires.

Eligibility

Age

18 - No limit years

Sex

MALE

Healthy Volunteers

Inclusion Criteria

•1. Subjects must be male (assigned male at birth) and 18 years or older.
•2. Subjects must demonstrate the ability to understand and provide written informed consent.
•3. Subjects must have histologically confirmed prostate cancer ( PCa) Note: Recruitment will be limited to a maximum of 50% of subjects with favorable intermediate-risk prostate cancer (PCa) Note: The histopathologic diagnosis must be obtained via "Prostate Biopsy (PB)", which for the purposes of the present study, is defined as both a systematic 12-core sextant random prostate biopsy and a targeted prostate biopsy. The targeted prostate biopsy can be performed via in-bore multiparemetric (mp) magnetic resonance imaging (MRI) prostate biopsy, cognitive mpMRI/ultrasound fusion prostate biopsy or software mpMRI/ultrasound fusion prostate biopsy. This "PB" must not be obtained greater than 1 year from the date of consent.
•4. Subjects must have chosen to get focal therapy (partial gland ablation) for the treatment of prostate cancer and must be scheduled for partial gland ablation/focal therapy with any energy modality within 6 months following informed consent.
•5. Subjects must have confirmed non-metastatic PCa following SOC screening for patients with unfavorable intermediate-risk and high risk PCa, a combination of computed tomography imaging of the abdomen and pelvis (CTAP) and technetium-99-mDP nuclear medicine bone scan (BS) and/or PSMA-PET imaging prior to enrollment. The imaging studies should be obtained within 6-months of enrollment.
•6. Subjects must be designated as Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 or Karnofsky Performance Status Scale Score ≥ 60%, (see Appendix A).
•7. Subjects must be fit to undergo general anesthesia and the FT surgical procedure, which includes adequate visualization of the prostate gland on transrectal ultrasound imaging, access to the urethra, perineum and rectum, as well as be tolerant of lithotomy positioning in the opinion of the treating investigator or the operating surgeon(s) if not the same as the treating investigator.

Exclusion Criteria

•1. Subject had prior or current PCa therapies, such as biologic, chemotherapy, hormone therapy, radiotherapy or surgery for PCa within last 12 months. Subjects who received radiation and/or androgen deprivation therapy for prostate cancer more than 12 months prior to diagnosis of recurrent prostate cancer will be eligible for the trial.
•2. Subjects with locally advanced, nodal or metastatic prostate cancer.
•3. Subjects who are unfit for pelvic mpMRI scanning (e.g., severe claustrophobia), permanent cardiac pacemaker, metallic implants that are likely to contribute to significant image artifacts, allergy or contraindication to gadolinium contrast agent.
•4. If the subject has an uncontrolled or major debilitating inter-current illness.
•5. Judgment by the treating investigator or PI that the subject is unsuitable to participate in the study and the subject is unlikely to comply with study procedures, restrictions, and requirements.

Locations (1)

University of Chicago Medicine Comprehensive Cancer Center

Chicago, Illinois, United States

Key Dates

Start Date

November 19, 2025

Primary Completion Date

August 1, 2028

Completion Date

August 1, 2028

Last Updated

February 17, 2026

Enrollment

ESTIMATED participants

Conditions

Prostate Cancer (Adenocarcinoma)Prostate Cancer (Diagnosis)Prostate Cancer Metastatic Disease

Interventions

PSMA PET/CT scan

RADIATION

Contacts

Abhinav Sidana, MD

CONTACT

(773) 702-4400 abhinav.sidana@bsd.uchicago.edu

Abhinav Sidana, MD

CONTACT

cancerclinicaltrials@bsd.uchicago.edu

Evolution of Lesions in Repeated Biparametric Prostate Magnetic Resonance Imaging

NCT07369570

Prostate Cancer (Diagnosis)

View study

RECRUITINGPHASE2

Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer

NCT06616597

Prostate Cancer (Adenocarcinoma)Metastatic Prostate Cancer

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 17, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

PSMA PET for Surveillance After Focal Therapy

Inclusion Criteria

Exclusion Criteria

Evolution of Lesions in Repeated Biparametric Prostate Magnetic Resonance Imaging

Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer

Dose De-escalation in Prostate Radiotherapy Using an MR-Linac in Two Fractions

Robot-Assisted Prostate Biopsy With a Novel Ultrasound Probe

Virtual Biopsy of Prostate Cancer Using PSMA PET and AI

Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617